Group 1 - Barclays raised its price target on CytomX Therapeutics, Inc. (CTMX) to $10 from $8 and maintained an Overweight rating [1] - Piper Sandler increased its price target to $10 from $6.50, maintaining an Overweight rating, following positive Phase I data on varsetatug maseatecan, which showed a 28% overall response rate and a 94% disease control rate [2] - Guggenheim initiated coverage with a Buy rating and a $10 price target, citing "extraordinary" antitumor activity from Varseta-M in heavily pre-treated patients [2] Group 2 - CytomX Therapeutics, Inc. develops conditionally activated biologics targeting the tumor microenvironment, including antibody-drug conjugates and T-cell engagers [3] - The company is expected to provide an update on approximately 100 metastatic colorectal cancer patients across various dose cohorts this quarter [2]

Core Insights - CytomX Therapeutics, Inc. (CTMX) is recognized as one of the best biotech stocks under $20, ranking eighth on a compiled list [1] - Analysts have raised price targets for CTMX, indicating positive sentiment ahead of upcoming data releases related to colorectal cancer treatments [2][3] Group 1: Analyst Ratings and Price Targets - Piper Sandler increased its price target on CTMX to $10 from $6.50, maintaining an Overweight rating, citing a 28% overall response rate and a 94% disease control rate from initial Phase 1 data [2] - Barclays analyst raised the price target for CTMX to $8 from $6, also maintaining an Overweight rating, highlighting an attractive risk-reward profile due to imminent readouts on colorectal cancer [3] Group 2: Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Probody therapeutics, which are designed to enhance cancer targeting and minimize off-tumor toxicity [4] - The company's pipeline includes innovative immuno-oncology and targeted therapies aimed at improving safety and efficacy for solid tumors and other serious diseases [4]